Evidence map›Paper›PMID 36387281›Full record

ReviewFrontiers in molecular biosciences2022

Tissue management in precision medicine: What the pathologist needs to know in the molecular era.

Ricella Souza da Silva, Regina Pinto, Luis Cirnes, Fernando Schmitt

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Next step of molecular pathology: next-generation sequencing in cytology.Journal of pathology and translational medicine · 2024
    Review
  5. Precision Medicine in Cytopathology.Surgical pathology clinics · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ricella Souza da SilvaIPATIMUP Diagnostics, IPATIMUP-Institute of Molecular Pathology and Immunology of Porto University, University of Porto, Porto, Portugal.
Regina PintoIPATIMUP Diagnostics, IPATIMUP-Institute of Molecular Pathology and Immunology of Porto University, University of Porto, Porto, Portugal.
Luis CirnesIPATIMUP Diagnostics, IPATIMUP-Institute of Molecular Pathology and Immunology of Porto University, University of Porto, Porto, Portugal.
Fernando SchmittIPATIMUP Diagnostics, IPATIMUP-Institute of Molecular Pathology and Immunology of Porto University, University of Porto, Porto, Portugal.
Universidade do Porto · PTCentre for Health Technology and Services Research · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine is "an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person." Among many medical specialists involved in precision medicine, the pathologists play an important and key role in the implementation and development of molecular tests that are in the center of decision of many therapeutic choices. Besides many laboratory procedures directly involved in the molecular tests, is fundamental to guarantee that tissues and cells collected for analysis be managed correctly before the DNA/RNA extraction. In this paper we explore the pivotal and interconnected points that can influence molecular studies, such as pre-analytical issues (fixation and decalcification); diagnosis and material selection, including the calculation of nuclei neoplastic fraction. The standardization of sample processing and morphological control ensures the accuracy of the diagnosis. Tissue or cytological samples constitutes the main foundation for the determination of biomarkers and development of druggable targets. Pathology and precision oncology still have a long way to go in terms of research and clinical practice: improving the accuracy and dissemination of molecular tests, learning in molecular tumor boards for advanced disease, and knowledge about early disease. Precision medicine needs pathology to be precise.

Indexed as

molecular pathologymorphological controloncology precisionpersonalized medicinesolid tumorstissue management

Identifiers

PMID36387281
PMCPMC9644376
OpenAlexW4307280478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.